Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer - TTL Representation

Raw ttl | Download


@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sct: <http://snomed.info/id/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

 a fhir:Group ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "179619"] ; # 
  fhir:meta [
fhir:versionId [ fhir:v "4" ] ;
fhir:lastUpdated [ fhir:v "2023-12-06T00:11:33.141Z"^^xsd:dateTime ] ;
    ( fhir:profile [
fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"^^xsd:anyURI ;
fhir:link <http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria>     ] )
  ] ; # 
  fhir:text [
fhir:status [ fhir:v "extensions" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Group 179619</b></p><a name=\"179619\"> </a><a name=\"hc179619\"> </a><a name=\"179619-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 4; Last updated: 2023-12-06 00:11:33+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-systematic-review-eligibility-criteria.html\">SystematicReviewEligibilityCriteria</a></p></div><p><b>Artifact related artifact</b>: No display for RelatedArtifact  (type: cite-as; citation: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-04. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619.)</p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>url</b>: <a href=\"https://fevir.net/resources/Group/179619\">https://fevir.net/resources/Group/179619</a></p><p><b>identifier</b>: FEvIR Object Identifier/179619</p><p><b>name</b>: SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer</p><p><b>title</b>: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p><strong>Study selection criteria</strong>\nTypes of Studies.\nRandomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.</p>\n<p>Types of participants.\nPatients aged ≥18 years with cytological or histological diagnosis of mHNPC.</p>\n</div><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 SystematicReviewEligibilityCriteria}\">SystematicReviewEligibilityCriteria</span></td></tr></table><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>membership</b>: Conceptual</p><p><b>combinationMethod</b>: All of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Study Design</span></p><p><b>value</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/181513 SEVCO:01003}\">randomized assignment</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Randomized controlled clinical trials (RCTs)</p>\n</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Study Design</span></p><p><b>value</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/181513 SEVCO:01011}\">Parallel cohort design</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>parallel design</p>\n</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Comparison</span></p><p><b>value</b>: GroupAssignment: ADT plus docetaxel vs. ADT alone</p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>compared the association of ADT and chemotherapy (docetaxel), versus ADT alone</p>\n</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 397669002}\">Age</span></p><p><b>value</b>: &gt;=18 years<span style=\"background: LightGoldenRodYellow\"> (Details: UCUM  codea = 'a')</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Types of participants.\nPatients aged ≥18 years</p>\n</div><p><b>method</b>: <span title=\"Codes:\">applied to participants in the studies</span></p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 64572001}\">Disease (disorder)</span></p><p><b>value</b>: <span title=\"Codes:\">metastatic hormone-naive prostate cancer</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Types of participants.\nPatients with cytological or histological diagnosis of mHNPC.</p>\n</div><p><b>method</b>: <span title=\"Codes:\">applied to participants in the studies</span>, <span title=\"Codes:\">cytological or histological diagnosis</span></p></blockquote></div>"
  ] ; # 
  fhir:extension ( [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact"^^xsd:anyURI ] ;
fhir:value [
a fhir:RelatedArtifact ;
fhir:type [ fhir:v "cite-as" ] ;
fhir:citation [ fhir:v "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-04. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619." ]     ]
  ] [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-author"^^xsd:anyURI ] ;
fhir:value [
a fhir:ContactDetail ;
fhir:name [ fhir:v "Brian S. Alper" ]     ]
  ] ) ; # 
  fhir:url [ fhir:v "https://fevir.net/resources/Group/179619"^^xsd:anyURI] ; # 
  fhir:identifier ( [
fhir:type [
      ( fhir:coding [
fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ;
fhir:code [ fhir:v "ACSN" ] ;
fhir:display [ fhir:v "Accession ID" ]       ] ) ;
fhir:text [ fhir:v "FEvIR Object Identifier" ]     ] ;
fhir:system [ fhir:v "https://fevir.net"^^xsd:anyURI ] ;
fhir:value [ fhir:v "179619" ] ;
fhir:assigner [
fhir:display [ fhir:v "Computable Publishing LLC" ]     ]
  ] ) ; # 
  fhir:name [ fhir:v "SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer"] ; # 
  fhir:title [ fhir:v "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"] ; # 
  fhir:status [ fhir:v "active"] ; # 
  fhir:publisher [ fhir:v "Computable Publishing LLC"] ; # 
  fhir:contact ( [
    ( fhir:telecom [
fhir:system [ fhir:v "email" ] ;
fhir:value [ fhir:v "support@computablepublishing.com" ]     ] )
  ] ) ; # 
  fhir:description [ fhir:v "**Study selection criteria**\nTypes of Studies.\nRandomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.\n\nTypes of participants.\nPatients aged ≥18 years with cytological or histological diagnosis of mHNPC."] ; # 
  fhir:useContext ( [
fhir:code [
fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ;
fhir:code [ fhir:v "evidence-communication" ] ;
fhir:display [ fhir:v "Evidence Communication" ]     ] ;
fhir:value [
a fhir:CodeableConcept ;
      ( fhir:coding [
fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ;
fhir:code [ fhir:v "SystematicReviewEligibilityCriteria" ] ;
fhir:display [ fhir:v "SystematicReviewEligibilityCriteria" ]       ] )     ]
  ] ) ; # 
  fhir:copyright [ fhir:v "https://creativecommons.org/licenses/by-nc-sa/4.0/"] ; # 
  fhir:membership [ fhir:v "conceptual"] ; # 
  fhir:combinationMethod [ fhir:v "all-of"] ; # 
  fhir:characteristic ( [
fhir:code [
fhir:text [ fhir:v "Study Design" ]     ] ;
fhir:value [
a fhir:CodeableConcept ;
      ( fhir:coding [
fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/181513"^^xsd:anyURI ] ;
fhir:code [ fhir:v "SEVCO:01003" ] ;
fhir:display [ fhir:v "randomized assignment" ]       ] )     ] ;
fhir:exclude [ fhir:v "false"^^xsd:boolean ] ;
fhir:description [ fhir:v "Randomized controlled clinical trials (RCTs)" ]
  ] [
fhir:code [
fhir:text [ fhir:v "Study Design" ]     ] ;
fhir:value [
a fhir:CodeableConcept ;
      ( fhir:coding [
fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/181513"^^xsd:anyURI ] ;
fhir:code [ fhir:v "SEVCO:01011" ] ;
fhir:display [ fhir:v "Parallel cohort design" ]       ] )     ] ;
fhir:exclude [ fhir:v "false"^^xsd:boolean ] ;
fhir:description [ fhir:v "parallel design" ]
  ] [
fhir:code [
fhir:text [ fhir:v "Comparison" ]     ] ;
fhir:value [
a fhir:Reference ;
fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ;
fhir:display [ fhir:v "GroupAssignment: ADT plus docetaxel vs. ADT alone" ]     ] ;
fhir:exclude [ fhir:v "false"^^xsd:boolean ] ;
fhir:description [ fhir:v "compared the association of ADT and chemotherapy (docetaxel), versus ADT alone" ]
  ] [
fhir:code [
      ( fhir:coding [
a sct:397669002 ;
fhir:system [ fhir:v "http://snomed.info/sct"^^xsd:anyURI ] ;
fhir:code [ fhir:v "397669002" ] ;
fhir:display [ fhir:v "Age" ]       ] )     ] ;
fhir:value [
a fhir:Quantity ;
fhir:value [ fhir:v "18"^^xsd:decimal ] ;
fhir:comparator [ fhir:v ">=" ] ;
fhir:unit [ fhir:v "years" ] ;
fhir:system [ fhir:v "http://unitsofmeasure.org"^^xsd:anyURI ] ;
fhir:code [ fhir:v "a" ]     ] ;
fhir:exclude [ fhir:v "false"^^xsd:boolean ] ;
fhir:description [ fhir:v "Types of participants.\nPatients aged ≥18 years" ] ;
    ( fhir:method [
fhir:text [ fhir:v "applied to participants in the studies" ]     ] )
  ] [
fhir:code [
      ( fhir:coding [
a sct:64572001 ;
fhir:system [ fhir:v "http://snomed.info/sct"^^xsd:anyURI ] ;
fhir:code [ fhir:v "64572001" ] ;
fhir:display [ fhir:v "Disease (disorder)" ]       ] )     ] ;
fhir:value [
a fhir:CodeableConcept ;
fhir:text [ fhir:v "metastatic hormone-naive prostate cancer" ]     ] ;
fhir:exclude [ fhir:v "false"^^xsd:boolean ] ;
fhir:description [ fhir:v "Types of participants.\nPatients with cytological or histological diagnosis of mHNPC." ] ;
    ( fhir:method [
fhir:text [ fhir:v "applied to participants in the studies" ]     ] [
fhir:text [ fhir:v "cytological or histological diagnosis" ]     ] )
  ] ) . #